紫杉醇/异环磷酰胺或长春瑞滨/异环磷酰胺化疗用于晚期非小细胞肺癌：癌症与白血病研究组B 9532研究
Paclitaxel/ifosfamide or navelbine/ifosfamide chemotherapy for advanced non-small cell lung cancer: CALGB 9532.
作者信息
Perry M C, Ihde D C, Herndon J E, Grossbard M L, Grethein S J, Atkins J N, Vokes E E, Green M R
机构信息
Division of Hematology/Oncology, Room 524, University of Missouri/Ellis Fischel Cancer Center, 115 Business Loop 70 W, Columbia, MO, USA.
出版信息
Lung Cancer. 2000 Apr;28(1):63-8. doi: 10.1016/s0169-5002(99)00129-4.
In order to explore non-cisplatin containing regimens for advanced non-small cell lung cancer, Cancer and Leukemia Group B conducted a randomized Phase-II study of two novel combinations, paclitaxel/ifosfamide and vinorelbine/ifosfamide. Both regimens were active with a 38% response rate (95% CI: 24%, 53%) and 31% (95% CI: 18%, 47%), respectively. Median survivals were 8.5 and 7.4 months. Toxicity, mostly neutropenia, was acceptable. These two combinations establish a 'proof of principle' that non-cisplatin containing regimens also have activity in this setting.
为了探索用于晚期非小细胞肺癌的不含顺铂的治疗方案，癌症与白血病B组开展了一项针对两种新联合方案（紫杉醇/异环磷酰胺和长春瑞滨/异环磷酰胺）的随机II期研究。两种方案均有活性，有效率分别为38%（95%置信区间：24%，53%）和31%（95%置信区间：18%，47%）。中位生存期分别为8.5个月和7.4个月。毒性主要为中性粒细胞减少，可接受。这两种联合方案确立了一个“原理验证”，即不含顺铂的治疗方案在此情况下也具有活性。
Zotero 插件